FDA Approves First Oral PCSK9 Inhibitor, Lipfendra, for Cholesterol Management
On 16 July 2026, the U.S. FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, to lower LDL cholesterol in adults with hypercholesterolaemia, including those with heterozygous familial hypercholesterolaemia. It offers a once-daily 20 mg tablet alternative to injectable PCSK9 inhibitors and demonstrated significant LDL-C reductions in Phase 3 trials.
On this page
Key Facts
- FDA approval date: 16 July 2026
- Drug name: Lipfendra (enlicitide)
- Drug type: Oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor
- Dose: 20 mg tablet once daily
- Indication: Adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia (HeFH)
- Mechanism of action: Inhibits PCSK9 pathway, increasing LDL receptor availability, promoting LDL cholesterol clearance from blood
- Clinical evidence: Two Phase 3 trials named CORALreef Lipids and CORALreef HeFH involving 3,207 adults
- LDL cholesterol reduction: Mean reduction approximately 56% compared to placebo at 24 weeks; post-hoc analyses observed up to 60% reduction excluding certain baseline data
- Common adverse events: Diarrhoea in 7% of Lipfendra patients vs 2% placebo; dizziness in 9% vs 4% placebo
Background & Context
Low-density lipoprotein cholesterol (LDL-C), commonly known as "bad cholesterol," contributes to cardiovascular disease risk. Familial hypercholesterolaemia is an inherited disorder characterized by elevated LDL-C levels, increasing atherosclerotic cardiovascular disease risk.
Prior to Lipfendra, PCSK9 inhibitors were only available as injectable formulations. PCSK9 inhibitors lower LDL-C by preventing the degradation of LDL receptors, thus enhancing clearance of LDL cholesterol from circulation.
Lipfendra’s oral formulation represents a significant advancement, potentially improving patient adherence and expanding treatment accessibility.
Other previously approved oral lipid-lowering agents include bempedoic acid (Nexletol) and bempedoic acid with ezetimibe (Nexlizet), which received expanded FDA indications in March 2024 for cardiovascular risk reduction and treatment of primary hyperlipidaemia.
Why This Matters for Exams / Exam Relevance
Competitive and medical exams frequently test knowledge on new drug approvals, mechanisms of action, and treatment protocols in cardiovascular pharmacology. Understanding Lipfendra as the first oral PCSK9 inhibitor, including its clinical trial results and therapeutic relevance for hypercholesterolaemia, is important for such examinations.
Additionally, candidates should be familiar with the difference between oral and injectable lipid-lowering therapies, relevant side effects, and indications for familial hypercholesterolaemia management.
Points to Remember
- Lipfendra (enlicitide) approved by FDA on 16 July 2026
- First oral PCSK9 inhibitor, 20 mg once daily tablet
- Approved for adults with hypercholesterolaemia including heterozygous familial hypercholesterolaemia
- Reduces LDL-C by approximately 56-60% compared to placebo in Phase 3 clinical trials
- Common side effects: diarrhoea and dizziness
- Represents oral alternative to injectable PCSK9 inhibitors
- Bempedoic acid-based drugs (Nexletol, Nexlizet) have expanded indications as of March 2024, but are distinct agents
Sources & Further Reading
| Document / Website | Link |
|---|---|
| FDA Approves First Oral PCSK9 Inhibitor - GKToday | Open FDA Approves First Oral PCSK9 Inhibitor - GKToday ↗www.gktoday.in |
| FDA: PCSK9 Inhibitors | Open FDA: PCSK9 Inhibitors ↗www.fda.gov |
| Lipid Management Guidelines | Open Lipid Management Guidelines ↗www.heart.org |